MA45165A - Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées - Google Patents

Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées

Info

Publication number
MA45165A
MA45165A MA045165A MA45165A MA45165A MA 45165 A MA45165 A MA 45165A MA 045165 A MA045165 A MA 045165A MA 45165 A MA45165 A MA 45165A MA 45165 A MA45165 A MA 45165A
Authority
MA
Morocco
Prior art keywords
influenzatigenic
polypeptides
modified
immunogenic compositions
associated immunogenic
Prior art date
Application number
MA045165A
Other languages
English (en)
Inventor
Eliud Oloo
Tod Strugnell
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MA45165A publication Critical patent/MA45165A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA045165A 2016-06-02 2017-06-02 Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées MA45165A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662344862P 2016-06-02 2016-06-02

Publications (1)

Publication Number Publication Date
MA45165A true MA45165A (fr) 2019-04-10

Family

ID=59227901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045165A MA45165A (fr) 2016-06-02 2017-06-02 Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées

Country Status (6)

Country Link
US (2) US10844097B2 (fr)
EP (1) EP3464328A1 (fr)
AU (2) AU2017272344B2 (fr)
CA (1) CA3026096A1 (fr)
MA (1) MA45165A (fr)
WO (1) WO2017210599A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196846A2 (fr) 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Polypeptides antigéniques de la grippe modifiés et compositions immunogènes correspondantes
AU2017272344B2 (en) 2016-06-02 2022-03-03 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US20240335525A1 (en) 2021-08-11 2024-10-10 Sanofi Pasteur Inc. Truncated influenza neuraminidase and methods of using the same
CN116284432A (zh) * 2022-09-09 2023-06-23 中山大学·深圳 一种乙型流感病毒重组蛋白疫苗及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2281838A1 (fr) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Utilisation d'acides nucleiques contenant des dinucleotides cpg non methyles dans le traitement des troubles associes aux lipopolysaccharides
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU2001259211B2 (en) 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
JP2009544322A (ja) 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
US8980281B2 (en) * 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
CN101820903A (zh) 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
EP2610345B1 (fr) 2007-11-27 2015-08-19 Medicago Inc. Particules pseudo-virales (VLP) de la grippe recombinantes produites dans des plantes transgéniques exprimant l'hémagglutinine
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
CN103957891B (zh) 2011-09-23 2017-01-11 美利坚合众国由健康及人类服务部部长代表 基于流感血凝素蛋白的新颖疫苗
IN2014DN05805A (fr) * 2012-02-07 2015-05-15 Univ Pittsburgh
AU2013240365B2 (en) 2012-03-30 2017-03-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
EP3149479A2 (fr) * 2014-05-30 2017-04-05 Sanofi Pasteur Inc. Expression et analyse de conformation de l'hémagglutinine de la grippe génétiquement modifiée
WO2016100926A1 (fr) 2014-12-19 2016-06-23 Oregon Health & Science University Co-administration synergique d'antigènes réactifs à large spectre optimisés par le calcul pour la grippe h5n1 humaine et aviaire
EP3303368A2 (fr) * 2015-06-02 2018-04-11 Sanofi Pasteur Inc. Polypeptides antigéniques de la grippe modifiés et compositions immunogènes correspondantes
WO2016196846A2 (fr) * 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Polypeptides antigéniques de la grippe modifiés et compositions immunogènes correspondantes
CA2986701A1 (fr) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Procedes d'optimisation de sequences nucleotidiques codant pour des proteines de la grippe ingenierisees
AU2017272344B2 (en) 2016-06-02 2022-03-03 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof

Also Published As

Publication number Publication date
US10844097B2 (en) 2020-11-24
US20190161519A1 (en) 2019-05-30
CA3026096A1 (fr) 2017-12-07
US12454555B2 (en) 2025-10-28
WO2017210599A1 (fr) 2017-12-07
AU2017272344A1 (en) 2018-12-13
US20210147488A1 (en) 2021-05-20
AU2022203625B2 (en) 2024-04-04
EP3464328A1 (fr) 2019-04-10
AU2017272344B2 (en) 2022-03-03
AU2022203625A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
SI3592393T1 (sl) Sprostljivi konjugati
EP3563863A4 (fr) Préparation lyophilisée
EP3513809A4 (fr) Composition médicinale
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3493800A4 (fr) Composition decannabis
EP3539514C0 (fr) Articulation de genou
DK3655017T3 (da) Farmaceutisk sammensætning
EP3490592A4 (fr) Compositions de glycanes immunogènes/thérapeutiques et utilisations associées
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3258174T3 (da) Ovn
BR112018000054A2 (pt) composições farmacêuticas liofilizadas
DK3528902T3 (da) Ringegelsammensætning
EP3560512A4 (fr) Composition de vaccin contre le zona
EP3430073A4 (fr) Composition de polyaryléthercétone
EP3725374C0 (fr) Composition d'écran solaire
EP3551291A4 (fr) Composition de shampoing sec
LT3110837T (lt) Tatk-cdkl5 sulieti baltymai, kompozicijos, sudėtys ir jų panaudojimas
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3583943T3 (da) Farmaceutisk sammensætning
EP3595691A4 (fr) Composition à base de plantes
DK3288640T3 (da) Tørshampoosammensætning
PL3551196T3 (pl) Kompozycje immunomodulujące
MA45165A (fr) Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées
SMT202400478T1 (it) Composizione farmaceutica
EP3443034C0 (fr) Composition